分享
首長信箱
分享
李柏昕醫師
引用
2025/05/14
醫師個人簡介
主治專長
肺癌、肺部結節、高壓氧治療、經皮氣切手術、睡眠呼吸障礙、肺阻塞、氣喘、一般胸腔疾病(咳嗽、肺結核、肺炎)、一般內科疾病、呼吸道相關疾病
專業經驗
臺中榮總胸腔部胸腔腫瘤科主治醫師
肺癌整合照護暨研究中心主治醫師
高壓氧治療中心主治醫師
肺癌整合照護暨研究中心主治醫師
高壓氧治療中心主治醫師
重要經歷/進修訓練
臺中榮總胸腔內科主治醫師
臺中榮總胸腔內科總醫師
臺中榮總內科部住院醫師
臺中榮總胸腔內科總醫師
臺中榮總內科部住院醫師
學歷
國立成功大學醫學系
國立中興大學轉譯醫學博士學位學程進修中
國立中興大學轉譯醫學博士學位學程進修中
專科證照
內科專科
胸腔暨重症專科
高壓氧專科
重症專科
肺癌專科
胸腔暨重症專科
高壓氧專科
重症專科
肺癌專科
教師資格
教育部定講師
國立陽明交通大學講師
胸腔暨重症加護醫學會專科醫師指導醫師
國立陽明交通大學講師
胸腔暨重症加護醫學會專科醫師指導醫師
研究興趣
肺癌、高壓氧。
進行中之計劃
[科技部計畫]
(1)雄性激素與雄性激素受體在肺癌致病機轉與抗藥性之探討 (NSTC 113-2314-B-075A-012 -MY2) 2024-2026
[院內計畫]
(1)肺癌病患接受標靶藥物後B型肝炎再活化之研究 (TCVGH-1123201A) 2023
(2)雄性荷爾蒙及其受體在肺癌致癌機轉之探討 (TCVGH-1133201A) 2024
(1)雄性激素與雄性激素受體在肺癌致病機轉與抗藥性之探討 (NSTC 113-2314-B-075A-012 -MY2) 2024-2026
[院內計畫]
(1)肺癌病患接受標靶藥物後B型肝炎再活化之研究 (TCVGH-1123201A) 2023
(2)雄性荷爾蒙及其受體在肺癌致癌機轉之探討 (TCVGH-1133201A) 2024
代表作
(1) Po-Hsin Lee, et al. Using a Polygenic Risk Score to Improve the Risk Prediction of Non–Small Cell Lung Cancer in Taiwan. JCO Precis Oncol. 8 (2024): e2400236.
(2) Po-Hsin Lee, et al. Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. Int. J. Mol. Sci. 2024, 25(13), 6949
(3) Po-Hsin Lee, et al. "Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma." Front. Oncol. 13 (2023): 1096683.
(4) Po-Hsin Lee, et al. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. J. Clin. Med. 2023, 12, 231.
(5) Po-Hsin Lee, et al. "Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma." Medicina 58.7 (2022): 908.
(6) Jia-Jun Wu, Po-Hsin Lee, et al. "Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)." Medicine 101.24 (2022): e29381.s
(7) Po-Hsin Lee, et al. "Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors." Sci. Rep. 11.1 (2021): 9381.
(8) Po-Hsin Lee, et al. "Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients." Anti-Cancer Drugs 32.10 (2021): 1099-1104.
(9) Po-Hsin Lee, et al. "Prognostic Factors to Predict ICU Mortality in Patients with Severe ARDS Who Received Early and Prolonged Prone Positioning Therapy." J. Clin. Med. 10.11 (2021): 2323.
(10) Po-Hsin Lee, et al."Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report." Clin. Lung Cancer (2020): S1525-7304.
(11) Po-Hsin Lee, et al. "Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection." Eur. J. Cancer 130 (2020): 272-274.
(12) Po-Hsin Lee, et al. "Pulmonary Embolism and Severe Asthma: Case Report and Literature Review." Medicina 55.10 (2019): 647.
(13) Po-Hsin Lee, et al. "Snakebite (Protobothrops mucrosquamatus)-related myositis." J. Formos. Med. Assoc. 118.7 (2019): 1168.
(14) Po-Hsin Lee, et al. "Coinfection of pneumocystis jiroveci pneumonia and pulmonary apergillosis in a non-HIV-infected patient." J Microbiol Immunol Infect 51.6 (2018): 860.
[Co-author]
(1) Mu-Han Peng, Yen-Hsiang Huang, Po-Hsin Lee, et al. "Osimertinib as Second-and≥ Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation." Cancers 16.24 (2024): 4174.
(2) Wei-Fan Ou, Po-Hsin Lee, Yen-Hsiang Huang, et al. "Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer." Ther Adv Med Oncol 16 (2024): 17588359241290718.
(3) Po-Hsiu Huang, Yao-Ting Huang, Po-Hsin Lee, et al. "Diagnosis of Legionnaires’ Disease Assisted by Next-Generation Sequencing in a Patient with COVID-19." Infection and Drug Resistance (2023): 355-362.
(4) Cheng-Hsiang Chu, Yen-Hsiang Huang, Lee, Po-Hsin, et al. Various impacts of driver mutations on the PD-L1 expression of NSCLC. PLoS One 17.8 (2022): e0273207.
[Non-SCI]
(1) Pei-Yi Shen, Po-Hsin Lee et al. "Carbon Monoxide Poisoning Induces Myocardial Injury With ECG ST Elevation: A Case Report and Literature Review." Thorac Med 39.3 (2024): 275-280.
(2) Lee, Po-Hsin, et al. “Comparing the Real-World Efficacy of Erlotinib and Afatinib in Treating Advanced Lung Squamous Cell Carcinoma.” Thorac Med 2023; 38: 187-198
(2) Po-Hsin Lee, et al. Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. Int. J. Mol. Sci. 2024, 25(13), 6949
(3) Po-Hsin Lee, et al. "Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma." Front. Oncol. 13 (2023): 1096683.
(4) Po-Hsin Lee, et al. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. J. Clin. Med. 2023, 12, 231.
(5) Po-Hsin Lee, et al. "Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma." Medicina 58.7 (2022): 908.
(6) Jia-Jun Wu, Po-Hsin Lee, et al. "Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)." Medicine 101.24 (2022): e29381.s
(7) Po-Hsin Lee, et al. "Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors." Sci. Rep. 11.1 (2021): 9381.
(8) Po-Hsin Lee, et al. "Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients." Anti-Cancer Drugs 32.10 (2021): 1099-1104.
(9) Po-Hsin Lee, et al. "Prognostic Factors to Predict ICU Mortality in Patients with Severe ARDS Who Received Early and Prolonged Prone Positioning Therapy." J. Clin. Med. 10.11 (2021): 2323.
(10) Po-Hsin Lee, et al."Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report." Clin. Lung Cancer (2020): S1525-7304.
(11) Po-Hsin Lee, et al. "Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection." Eur. J. Cancer 130 (2020): 272-274.
(12) Po-Hsin Lee, et al. "Pulmonary Embolism and Severe Asthma: Case Report and Literature Review." Medicina 55.10 (2019): 647.
(13) Po-Hsin Lee, et al. "Snakebite (Protobothrops mucrosquamatus)-related myositis." J. Formos. Med. Assoc. 118.7 (2019): 1168.
(14) Po-Hsin Lee, et al. "Coinfection of pneumocystis jiroveci pneumonia and pulmonary apergillosis in a non-HIV-infected patient." J Microbiol Immunol Infect 51.6 (2018): 860.
[Co-author]
(1) Mu-Han Peng, Yen-Hsiang Huang, Po-Hsin Lee, et al. "Osimertinib as Second-and≥ Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation." Cancers 16.24 (2024): 4174.
(2) Wei-Fan Ou, Po-Hsin Lee, Yen-Hsiang Huang, et al. "Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer." Ther Adv Med Oncol 16 (2024): 17588359241290718.
(3) Po-Hsiu Huang, Yao-Ting Huang, Po-Hsin Lee, et al. "Diagnosis of Legionnaires’ Disease Assisted by Next-Generation Sequencing in a Patient with COVID-19." Infection and Drug Resistance (2023): 355-362.
(4) Cheng-Hsiang Chu, Yen-Hsiang Huang, Lee, Po-Hsin, et al. Various impacts of driver mutations on the PD-L1 expression of NSCLC. PLoS One 17.8 (2022): e0273207.
[Non-SCI]
(1) Pei-Yi Shen, Po-Hsin Lee et al. "Carbon Monoxide Poisoning Induces Myocardial Injury With ECG ST Elevation: A Case Report and Literature Review." Thorac Med 39.3 (2024): 275-280.
(2) Lee, Po-Hsin, et al. “Comparing the Real-World Efficacy of Erlotinib and Afatinib in Treating Advanced Lung Squamous Cell Carcinoma.” Thorac Med 2023; 38: 187-198
其他
(2024) 胸重醫學會口頭報告原著論文優秀論文獎第一名
(2024) 臺中榮總院級臨床教學績優醫師、主治醫師組優良論文獎第三名
(2023) 臺中榮總院級臨床教學績優醫師
(2023) 第一屆煦陽溫和大地優良醫學論文獎 青年醫師-住院醫師組 第一名
(2022) 臺中榮總青年醫師優良論文第二名
(2020) EBM實證醫學第二名
(2020) 胸重醫學會Junior Research Award優秀論文獎
(2020) 內科部研究進度報告第二名
(2020) 臺中榮總院級臨床教學績優住院醫師
(2019) 內科學誌優秀論文獎綜論類第一名
(2024) 臺中榮總院級臨床教學績優醫師、主治醫師組優良論文獎第三名
(2023) 臺中榮總院級臨床教學績優醫師
(2023) 第一屆煦陽溫和大地優良醫學論文獎 青年醫師-住院醫師組 第一名
(2022) 臺中榮總青年醫師優良論文第二名
(2020) EBM實證醫學第二名
(2020) 胸重醫學會Junior Research Award優秀論文獎
(2020) 內科部研究進度報告第二名
(2020) 臺中榮總院級臨床教學績優住院醫師
(2019) 內科學誌優秀論文獎綜論類第一名